Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia.

Blood - 3 Apr 2025

Lyu Junhua, Liu Yuxuan, Liu Ningning, Vu Hieu S, Cai Feng, Cao Hui, Kaphle Pranita, Wu Zheng, Botten Giovanni A, Zhang Yuannyu, Wang Jin, Achyutuni Sarada, Gao Xiaofei, Iacobucci Ilaria, Mullighan Charles G, Chung Stephen S, Ni Min, DeBerardinis Ralph J, Xu Jian

Abstract excerpt

ABSTRACT: Recurrent isocitrate dehydrogenase (IDH) mutations catalyze nicotinamide adenine dinucleotide phosphate (NADPH)-dependent production of oncometabolite (R)-2-hydroxyglutarate (R-2HG) for tumorigenesis. IDH inhibition provides clinical response in a subset of acute myeloid leukemia (AML) cases; however, most patients develop resistance, highlighting the need for more effective IDH-targeting therapies. By...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Cell Line, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glycolysis

Share to Hyaluronan Receptors

Share to Isocitrate Dehydrogenase

Share to Leukemia, Myeloid, Acute

Share to Mutation

Share to Protein Degradation and Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 39841003
DOI: 10.1182/blood.2024027207
PMCID: PMC12002223

Genes

CD44

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CD44-mediated metabolic rewiring is a targetable dependency of IDH-mutant leukemia.PMID 39841003Read ↗

Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.Semantic proximity Read ↗

Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation.Semantic proximity Read ↗

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.Semantic proximity Read ↗

Targeting IDH Mutations in AML: Wielding the Double-edged Sword of Differentiation.Semantic proximity Read ↗

Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions.Semantic proximity Read ↗

Illuminating the cross-talk between tumor metabolism and immunity in IDH-mutated cancers.Semantic proximity Read ↗

Deconvoluting clonal and cellular architecture in IDH-mutant acute myeloid leukemia.Semantic proximity Read ↗

The role of IDH mutations in acute myeloid leukemia.Semantic proximity Read ↗

Phospholipid metabolic adaptation promotes survival of IDH2 mutant acute myeloid leukemia cells.Semantic proximity Read ↗

Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML.Semantic proximity Read ↗

Profiling the Effect of Targeting Wild Isocitrate Dehydrogenase 1 (IDH1) on the Cellular Metabolome of Leukemic Cells.Semantic proximity Read ↗

Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.